患者对不明原因症状(MUS)医疗沟通体验的混合方法研究
Patients’ experience with medical communication about medically unexplained symptoms
基于法国 ComPaRe 电子队列的大型患者报告数据显示,MUS 患者满意度的主要决定因素是对其痛苦的明确认可,而非具体的诊断标签。研究发现,否认疾病存在的解释会引发强烈的负面反应,而富有同理心的功能性模型则有助于建立信任。
Introduction
Medically unexplained symptoms (MUS) are persistent complaints for which no sufficiently explanatory pathology is identified after appropriate medical evaluation1,2,3,4,5. They are multifactorial in origin, with potential contributions from biomedical, physiological, and behavioral processes1,6. MUS can persist for months and may overlap with various clinical entities, such as myalgic encephalomyelitis/ chronic fatigue, long COVID, hypermobile Ehlers–Danlos or mast cell activation syndromes, as well as with environmental intolerance syndromes. Historically, persistent physical symptoms without an obvious structural organic cause have been labeled as MUS. This framework inherently suggests the failure of the classical biomedical diagnostic process. However, nowadays it is well acknowledged that it is not appropriate to label these symptoms as “medically unexplained” since several cognitive and behavioral explanations have been documented that shed light on the close interaction between body and mind. A more appropriate denomination (“persistent somatic symptoms”) has been proposed recently by Löwe et al.1, avoiding Cartesian mind-body dualism and patient-perceived stigma3,5,7,8. In some cases, MUS may also meet functional somatic disorder (FSD) criteria when they last more than 6 months and are associated with inappropriate thoughts and emotions regarding symptoms9,10,11,12.
MUS account for up to 50% of primary care consultations and around 20–25% of secondary care referrals11,13,14,15. They are associated with significant functional impairment, reduced quality of life, and high rates of work disability16,17. They also contribute substantially to healthcare burden, with annual costs estimated at £18 billion in the UK alone, driven by repeated consultations, investigations, and specialist referrals18.
Diagnosing and managing MUS is challenging due to the lack of consensus terminology and specific physical or biological findings, insufficient physician training, and limited evidence-based therapeutic options16,19,20,21,22,23,24,25,26,27. These barriers, compounded by time constraints and the complexity of patients’ narratives, often lead to fragmented care and repeated investigations: a pattern described as “medical nomadism” leading to inconsistent explanations and care23,24,28,29. Current literature on MUS emphasizes the benefits of legitimizing symptoms, maintaining a therapeutic alliance, and acknowledging uncertainty, but offers limited evidence on how best to communicate about MUS25,26,27,30. Recent mixed-methods studies across European healthcare settings underscore the importance of co-designed, non-stigmatizing explanatory models that improve patient reassurance and healthcare adherence31,32,33. Furthermore, qualitative evidence highlights that receiving a specific validation label, such as fibromyalgia, acts as a critical pivot point that can significantly reduce diagnostic wandering, provided it is delivered alongside an empathetic and collaborative clinical narrative34. To the best of our knowledge, large-scale patient-reported data evaluating how different wordings or explanatory strategies influence patient-reported experience in MUS remain scarce. The aim of our study was therefore to explore patients’ experiences of medical communication on MUS.
Here, we show that the primary determinant of patient satisfaction is the explicit validation of suffering rather than the diagnostic label itself. We find that explanations denying the disease trigger overwhelming negative reactions, whereas functional models framed with empathy and explanatory models foster trust.
Methods
Study design and data sources
We conducted a mixed-methods study, nested within the Community of Patients for Research (ComPaRe), an ongoing citizen science project based on a nationwide e-cohort of 65,000 patients with at least one chronic disease, in France (www.compare.aphp.fr). All participants provide electronic consent before participating in the e-cohort35. ComPaRe was approved by the Institutional Review Board of Hôtel-Dieu Hospital, Paris (IRB: 0008367).
Population
Patients were adults (>18 years old), with at least one chronic condition (defined as a condition requiring healthcare for at least 6 months) and active in ComPaRe in the last 12 months at the time of study launch (i.e., between February 2024 and February 2025).
Data collection
Participants completed an online questionnaire in which they first reported whether they experienced chronic symptoms (>6 months). Those responding positively completed the Somatic Symptom Disorder Criteria Scale (SSD-12)36 to assess symptom burden and the EQ-5D-5L37,38 to evaluate health-related quality of life. They were then asked whether any symptom had no clear medical explanation: affirmative responses defined the presence of at least one MUS and led to (1) a series of closed-ended questions documenting the nature, duration, and disability of MUS, the explanations and diagnoses received, and the care pathway (consultations, investigations, and treatments); and (2) an open-ended question exploring patients’ experiences of diagnostic communication: “How did you feel about the different explanations given to you (what were the positive and negative points)?” (Supplementary Note 1). Participants were encouraged to detail both positive and negative points, linking them to specific terms or explanations received.
The questionnaire was tested to ensure its clarity during two pilot phases in January and February 2025 by 15 participants of ComPaRe and two expert patients themselves suffering from disabling MUS. The final version was sent on February 27th 2025, to the population of the study. Five e-mail reminders were sent during the study period (February–May 2025). In addition to the questionnaire, participants’ demographic and clinical data (comorbidities, age, gender, and educational level) were extracted from ComPaRe data.
Qualitative analysis framework
Open-ended responses were analyzed using inductive thematic analysis following Braun and Clarke’s six-step framework39.
-
(1)
Familiarization with the data: one investigator (ER) read the entire dataset of open-ended responses to grasp the depth of patients’ narratives and identified those explicitly referring to experiences regarding their physician’s explanations. When several types of explanations were reported, only experiences allowing a clear link with a specific type of explanation were retained.
-
(2)
Generating initial codes: independent coding (identifying specific portions of text related to unique and defined patients’ perceptions) was conducted by two investigators (ER, BR) until data saturation was reached. ER coded the remaining responses, with regular discussion with BR and, if needed, a third investigator (VTT).
-
(3)
Searching for themes: ER and BR grouped the initial codes into concepts and aggregated them into broader candidate sub-themes and themes.
-
(4)
Reviewing themes: the candidate themes were checked against the coded extracts and the entire dataset to ensure internal homogeneity and external heterogeneity40.
-
(5)
Defining and naming themes: ER, BR, and VTT finalized the conceptual essence of each theme, resulting in the eight final overarching themes referring to patients’ experiences.
-
(6)
Producing the report: occurrences of each theme were quantified and analyzed, overall and according to the type of explanation or diagnosis received.
Explanations provided by healthcare professionals were categorized into three predefined groups: explicit diagnoses or mechanistic explanations, explanations denying the presence of a disease (e.g., “it’s in your head”), or acknowledgment of the physician’s uncertainty (“I don’t know”). Patient-reported explicit diagnoses were classified into four distinct categories: (1) labels suggesting somatic/organic diseases (subsequently referred to as « organic labelled » in the text), including controversial medical conditions with a presumed biological cause, often operationalized by patient advocacy groups (e.g., myalgic encephalomyelitis, mast cell activation syndrome, chronic lyme disease, long COVID, and hypermobile Ehlers–Danlos syndrome); (2) mechanistic explanations, referring to proposed biological or environmental processes (e.g., leaky gut, microbiota imbalance, heavy metal toxicity, or food/environmental hypersensitivities) without a criteria-validated disease label; (3) functional disorder diagnoses, which include criteria-defined central or functional syndromes (e.g., irritable bowel syndrome, spasmophilia, somatoform disorders, nociplastic pain, and fibromyalgia); and (4) psychiatric diagnoses (e.g., anxiety or depressive disorders) (Supplementary Note 2).
Eight overarching themes were identified, referring to patients’ experiences following their physician’s explanations. Negative experiences included a lack of consideration from physicians, negative emotions, dissatisfaction with the diagnostic procedure, and dissatisfaction with proposed therapeutic management. In contrast, positive experiences encompassed the quality of the doctor-patient relationship, senses of relief and revaluation, satisfaction with the diagnostic procedure, and with proposed therapeutic management.
We counted the number of occurrences of each theme, overall and according to the type of explanation received. Among participants who reported having received an explicit diagnosis or a mechanistic explanation, counts were also separated by diagnosis type (“organic labelled,” mechanistic, psychiatric, or functional explanation) to explore differences in patients’ experience.
Descriptive analyses
Descriptive analyses were performed for patients with persistent symptoms (>6 months) and, among them, for those with MUS. Variables included gender, age, education, comorbidity profile (grouped by type), symptom categories, number of physicians consulted, investigations, SSD-12 score, EQ5D-5L score, and treatments. Comorbidities were grouped into six clinical categories. Symptoms were grouped according to the four main categories described in the definition of the bodily distress syndrome definition41.
Statistics and reproducibility
The data were weighted using calibration on margins to represent the French population of patients with chronic conditions, with weights derived from the 2021 Santé Publique France data42 and estimates of the SSD-12 score distribution in patients with both general medical diseases requiring outpatient hospital care and selected comorbid disorders requiring primary care43. Analyses were performed using the icarus and survey packages in R (version 2024.12.1).
The study sample size was determined by the total number of active participants meeting the inclusion criteria within the ComPaRe e-cohort platform during the pre-specified recruitment window, maximizing statistical power for qualitative text saturation. For the quantitative components, statistical significance between patient sub-groups was evaluated using two-sided chi-squared tests or two-sided Student’s t tests (Wald tests) where appropriate. A p-value below 0.05 was considered statistically significant. Qualitative reproducibility was secured by conducting double independent coding across two separate thematic analysts, with inter-rater discrepancies resolved via iterative consensus-building sessions.
Ethics approval and consent to participate
The ComPaRe e-cohort received ethical approval from the Comité de protection des personnes – Île de France 1 [French Consultative Committee for the protection of persons] (IRB: 0008367), and from the Comité consultatif sur le traitement de l’information en matière de recherche dans le domaine de la santé [French Consultative Committee on Information Processing in Health Research] (CCTIRS, No. 16-395bis). Approval was also granted by the CNIL (No. 916397, DR-2016-459) and by CEREES (April 11, 2019). All participants provided informed electronic consent prior to inclusion. Data collection and study procedures comply with the French data protection law and the Declaration of Helsinki.
Results
Participants characteristics
Between February 27th and May 4th 2025, 8544 individuals were invited to participate in the study, among which 4041 (47.3%) accessed the questionnaire, and 3036 participants gave informed consent and completed the questionnaire (75% participation rate). Among these, 2673 (88%) reported persistent symptoms and 1786 (69.9%) reported at least one medically unexplained symptom (MUS) (Supplementary Fig. 1). Characteristics of the weighted and unweighted populations of participants are reported in Supplementary Tables 1 and 2.
Main characteristics of the weighted population of participants are presented in Table 1: among participants reporting MUS, 65.8% were women, with a mean age of 51.3 years (SD 16.6), and high symptom burden (mean SSD-12 score of 26.4 (SD 10.3)). The baseline demographic and clinical characteristics of the target MUS cohort remained highly comparable to the wider chronic disease e-cohort with persistent symptoms.
Supplementary Tables 4 and 5 describe the characteristics of participants with MUS, according to the type of explanation they reported receiving for those whose data allowed such analysis (n = 1487). Most patients reported receiving several types of explanations or diagnoses for their MUS: 1086 (91%) received two or more, 830 (69%) received three or more, 510 (43%) received four or more (Supplementary Fig. 3). One thousand one hundred ninety-seven participants (80.5%) reported receiving an explicit diagnosis or mechanistic explanation, 979 (65.8%) reported being told that their symptoms were “all in their head,” and 691 (46.5%) reported that their physician acknowledged not knowing the cause of their MUS. Their clinical profiles were broadly similar: predominantly female (~80%), mean age approximately 48 years, median of three chronic diseases, and frequent psychiatric comorbidities (23–30%) (Supplementary Tables 4 and 5).
Patients’ experience with communication about MUS
In total, 1025 reported their experience regarding their physician’s explanations of the MUS, representing 1438 open-ended answers linking a specific explanation to an experience, since individual narratives could refer to multiple explanations and could therefore be analyzed more than once. These data represented 130,716 words in total. Thematic analysis identified 20 sub-themes and 57 concepts across the eight main themes (Supplementary Fig. 4).
Negative experiences with reports of lack of consideration from doctors included abusive and demeaning medical attitudes, lack of empathy and openness, feeling not taken seriously, discrimination, and perceived blame and burden. Dissatisfaction with the diagnostic procedure included diagnostic wandering, lack of medical explanations, and lack of diagnostic continuity. Dissatisfaction with therapeutic management included lack of therapeutic solution and uncertainty about the future. Negative emotions included guilt and self-devaluation, helplessness, anger, shock, and feelings of abandonment.
In contrast, positive experiences referred to satisfaction with diagnosis, including clear medical explanations and thorough diagnostic assessment. Satisfaction with therapeutic management included therapeutic proposals. Relief and revaluation included senses of relief, recognition and belonging, while the quality of doctor-patient relationship included listening skills and acknowledgment of uncertainty. Sub-themes thus captured both the emotional experience of patients and the perceived quality of care delivered. Examples of verbatims can be found in Supplementary Table 6.
“It’s in your head”
Negative themes dominated among patients who reported being told that their symptoms were “in their head”: almost all of them (99.7%) described negative experiences (Table 2). The most frequent sub-themes concerned dissatisfaction with the diagnostic procedure, lack of therapeutic options, and poor consideration from doctors. No positive theme, such as relief or recognition, was identified in this group. As one participant described: “My various pains (…) were very real, but most of the doctors and specialists I met were unable to make a diagnosis. In the best cases: ‘there’s nothing wrong’, ‘it could be fibromyalgia, but I’m not convinced’ or ‘no explanation’, in the worst cases: ‘it’s all in your head’…”.
Explicit diagnoses (Table 3)
Patients who received an explicit diagnosis reported a more balanced experience, with 47.5% mentioning positive themes, and 85.8% reporting at least one negative theme (Table 2). Relief, recognition, and satisfaction with the doctor-patient relationship were reported in 30.4% and 16.8% of cases, respectively, but 28.2% of patients reported diagnostic wandering and 20% a lack of medical explanation. Within this group, experiences varied depending on the type of diagnosis. Patients who received a diagnosis of « organic labelled » disease (such as long COVID, Ehlers–Danlos syndrome, or chronic Lyme disease) emphasized recognition and legitimacy, though often accompanied by frustration at limited treatment options: “(…) Long covid/chronic fatigue syndrome/myalgic encephalomyelitis—(allow) feeling heard and taken seriously, (but generate) despair at the lack of treatments, tests, tangible evidence, administrative recognition (…)”. In contrast, patients given a functional disorder diagnosis less frequently described dissatisfaction with therapeutic management (17.5%) than people with « organic labelled » diseases (26.5%). The functional disorder patients also valued the educational, empathetic approach of physicians: “(…) Others were very humane and educational, explaining the close link that could exist between the unconscious and the body, and that it was not uncommon to meet patients with the same picture. They were able to give me direction (for treatment) (…)”.
“I don’t know”
Patients who were told by physicians that they didn’t know the cause of their symptoms also reported mainly negative experiences (92.1%), such as dissatisfaction with the diagnostic procedure, lack of therapeutic proposals, and feelings of abandonment. In contrast, positive themes were more rarely mentioned (21.4%). Importantly, only 1.2% of patients in this group reported relief or feeling revalued, underscoring the detrimental impact of diagnostic silence. However, 8.5% of them mentioned that they would prefer physicians to acknowledge their doubts and limitations of knowledge, rather than deny the veracity of their symptoms: “When people say it’s all in your head, it’s irritating because it means they don’t believe our pain! Some doctors don’t understand what can be understood, and I’d rather they just tell me they don’t know. (…)”.
Discussion
Here, we described the experience of over 1700 patients with MUS regarding their physician’s explanations and found three categories of communication: explicit diagnoses or mechanistic explanations, explanations denying the presence of a disease (e.g., “it’s in your head”), or acknowledgment of the physician’s uncertainty (“I don’t know”). One of the most consistent findings is that patients who reported receiving explanations denying the presence of a disease described overwhelmingly negative experiences. These explanations were associated with strong emotional reactions, such as anger, guilt, or helplessness, and a feeling of devaluation. This perception could have significant consequences on the therapeutic alliance and engagement with care44,45. The proportion of patients reporting this type of explanation was high (65.8% of the MUS group), suggesting that such types of explanation remain common in clinical encounters, despite growing awareness of its potentially harmful impact19,46. The concept of the “number needed to offend” established by Stone et al.44 perfectly captures our qualitative findings regarding how easily standard dismissive formulations, such as “it’s all in your head,” can backfire and break the therapeutic alliance, even when bundled with an explicit clinical diagnosis.
Conversely, receiving an explicit diagnosis or mechanistic explanation, even if it did not correspond to a formally recognized disease entity, was generally associated with more positive experiences. Among those, participants who were given an explicit diagnosis, including diseases with alleged purely biological causes but also functional disorders diagnoses (e.g., irritable bowel syndrome, fibromyalgia), often reported a sense of relief, improved self-worth, and validation of their suffering. These findings echo prior qualitative research showing that receiving a diagnosis, even a provisional one, can help patients make sense of their symptoms, reduce uncertainty, and foster trust in the physician47,48,49. While diagnosis is central to medical care, offering patients a narrative helps making sense of their symptoms and legitimizing their suffering; its absence leaves patients in a state of anxiogenic uncertainty, with no prognosis and no explanation for their disability47,49,50. It is, however, important to note that in our study several patients reported that they preferred when physicians acknowledged their uncertainty instead of denying or dismissing patients’ suffering and symptoms, a specific point that has already been highlighted in the literature51. Patients who received a diagnosis of a controversial or emerging condition, such as mast cell activation syndrome or long COVID, often expressed significant relief and satisfaction with the explanation provided. These labels appeared to fulfill a need for medical acknowledgement. However, our data suggest that these patients were less likely to receive therapeutic proposals in line with the diagnosis, pointing to a potential gap between diagnostic naming and actionable care. While these somatic labels are well-received by patients seeking validation, they carry documented risks of overdiagnosis, diagnostic overshadowing, and direct iatrogenic harm52. Crucially, as Veldmeijer et al. describe, purely somatic or psychiatric labeling can inadvertently build a narrative “cage” that restricts the patient, while failing to provide any actionable pathophysiological explanations53. Although sometimes strongly rejected and a source of feeling of non-recognition, they were well accepted by many patients. In some cases, patients reported more therapeutic satisfaction despite the absence of a specific pharmacological treatment, highlighting the value of recognition and narrative coherence in the diagnostic encounter, as well as the importance and benefits of understanding the underlying mechanisms of the disease47. Rather than leaving symptoms unexplained or fixed under immutable organic claims, a formalized functional framework allows clinicians to communicate evidence-based pathophysiological mechanisms, such as central sensitization or nociplastic pathways. Providing these underlying mechanisms provides narrative coherence to the diagnostic encounter, which is an essential prerequisite for effective therapeutic management. Ultimately, this enables patients to achieve greater satisfaction, even in the absence of specific pharmacological options, and facilitates active adherence to targeted strategies, such as psychoeducation, tailored physical activity, and cognitive-behavioral therapy, thereby curtailing medical nomadism1,21,54,55. Even in the case of “organic labelled” disease diagnoses, evidence-based therapies are non-pharmacological and often similar to those used in functional disorders56. However, they may be less well accepted since they do not correspond to the pathophysiological explanations received.
Psychiatric diagnoses, in contrast, were often associated with stigma and dissatisfaction, underscoring the need for sensitive communication and public education on the nature and recognition of psychiatric conditions given their frequency57,58.
Across explanation categories, there was a striking similarity in patient profiles. Whether patients received a functional, psychiatric, mechanistic, or “organic labelled” disease diagnosis, an explanation denying the presence of a disease, or an acknowledgment of uncertainty, their demographic and clinical characteristics were largely comparable. Although our data cannot be used to assess the accuracy of medical diagnosis, this suggests that explanation framing is influenced more by physician interpretation, habits, or training than by patient-specific factors. Previous studies have similarly highlighted the variability in how MUS are approached across physicians, with explanations often shaped by the physician’s beliefs, training, professional culture, and available resources20,55,59. Noteworthy, this situation is allowed by the large overlap between clinical entities’ criteria. Indeed, 91% of patients in our study had received more than one explanation or diagnosis.
The historical lack of progress in optimizing medical communication for persistent somatic symptoms cannot be attributed solely to individual provider attitudes. Biomedically focused academic training, rooted in historical mind-body dualism, often leaves clinicians poorly equipped to handle symptoms that lack objectifiable abormalities60,61. Furthermore, strict constraints during standard consultations severely hinder the establishment of the nuanced, patient-centered narratives required for MUS management. Implementing restructured care models, such as structured communication tools, could offer the structural buffer necessary to build therapeutic alliances60,62.
This study has several strengths. First, our questionnaire was tested during two pilot phases and validated by expert patient partners. Second, our study drew on a large and diverse sample of patients with chronic conditions, recruited through the ComPaRe e-cohort, and we used calibration on margins to generate estimates generalizable to the general population with chronic conditions. Finally, the qualitative analysis was conducted rigorously, with independent coding by two researchers and triangulation by a third researcher, enhancing credibility and minimizing interpretive bias.
However, several limitations should be noted. The use of an online questionnaire, rather than in-person interviews, may have limited the richness of individual responses. This trade-off allowed for greater reach and diversity of participants, but constrained the ability to probe or clarify ambiguous answers. In particular, a large proportion of verbatims could not be used for our comparative qualitative analysis by type of diagnosis, because reported feelings could not be linked to a particular type of diagnosis. Additionally, despite calibration on margins, the ComPaRe cohort may not be representative of the broader MUS population, as participants tend to be younger, more educated, and more frequently women. Finally, it is to be noted that the number of times a theme appears reflects its importance and significance to participants rather than its frequency. Some feelings may indeed have been felt by patients who did not think to report them. Results should therefore be interpreted in terms of perceived importance rather than statistical prevalence.
Finally, two important points should be noted. First, our objective was not to evaluate the accuracy of the explanations delivered, but rather to understand what patients recalled and retained from the communication process, and how the content and framing of explanations impacted their experience. Noteworthy, significant discrepancies frequently exist between objective documentation and a patient’s subjective understanding or memory of a consultation. Our study only captures the internalized experience of medical communication, which may be subject to memory bias or post-hoc cognitive reframing63. Second, no causal relationship can be inferred between the type of diagnosis or explanation received and the emotional response of patients. It is even possible that the causality operates in the opposite direction: certain patient profiles, based on prior experiences, expectations, or communication habits, may influence the type of explanation or diagnosis they ultimately receive from physicians.
Our findings have actionable implications for medical curricula. Training programs must shift from a traditional, defensive focus (e.g., over-investigation or binary organic vs. psychiatric sorting) toward experiential, simulation-based communication training60. Medical students and junior doctors must be taught how to deliver coherent functional explanatory models and how to acknowledge diagnostic uncertainty without triggering feelings of abandonment or non-recognition in patients. Prospective longitudinal studies have evaluated the concrete impact of standardized communication toolkits (such as shared-decision aids or validated wording guidelines) on long-term patient outcomes and medical skills60,62. Future studies should assess their impact on healthcare utilization costs.
Conclusions
Overall, our findings underscore that patients’ experiences are shaped less by the specific diagnostic label provided than by the way explanations are framed and communicated. Explanations perceived as dismissive were consistently associated with negative emotional reactions. In contrast, explanations that acknowledged patients’ symptoms as legitimate and offered a structured, comprehensible model were more likely to be accepted. Our results therefore highlight that the central issue is not the nature of the diagnosis itself, but the extent to which physicians provide meaningful, respectful, and actionable explanations. Although time constraints, limited training, and resource gaps may complicate such communication in the context of MUS1,21,46,54,55,64, when diagnostic certainty is elusive, the way physicians speak to patients, and the words they chose, may be as therapeutically important as any specific intervention.
Data availability
All data generated and used in the study are from the ComPaRe e-cohort platform. De-identified data presented in this study are available to public research teams for health-related research in the public interest. Researchers who wish to access the data must comply with the conditions detailed on https://compare.aphp.fr. Contact for access requests is contact.compare@aphp.fr. All requests for data are examined by the ComPaRe scientific committee and responded within 3 months from submission.
References
Löwe, B. et al. Persistent physical symptoms: definition, genesis, and management. Lancet 403, 2649–2662 (2024).
Kroenke, K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int. J. Methods Psychiatr. Res. 12, 34–43 (2003).
Löwe, B. et al. Persistent SOMAtic symptoms ACROSS diseases—from risk factors to modification: scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211). BMJ Open 12, e057596 (2022).
Henningsen, P., Zipfel, S. & Herzog, W. Management of functional somatic syndromes. Lancet 369, 946–955 (2007).
Marks, E. M. & Hunter, M. S. Medically unexplained symptoms: an acceptable term? Br. J. Pain 9, 109–114 (2015).
Smakowski, A., Rosmalen, J., Löwe, B., Burton, C. & Toussaint, A. Empirical assessment of functional somatic disorder (FSD): frequency, applicability, and diagnostic refinement in a population-based sample. BMC Med. 23, 221 (2025).
Picariello, F., Ali, S., Moss-Morris, R. & Chalder, T. The most popular terms for medically unexplained symptoms: the views of CFS patients. J. Psychosom. Res. 78, 420–426 (2015).
Klaus, K. et al. The distinction between ‘medically unexplained’ and ‘medically explained’ in the context of somatoform disorders. Int. J. Behav. Med. 20, 161–171 (2013).
Hiller, W., Rief, W. & Brähler, E. Somatization in the population: from mild bodily misperceptions to disabling symptoms. Soc. Psychiatr. Epidemiol. 41, 704–712 (2006).
Aggarwal, V. R., McBeth, J., Zakrzewska, J. M., Lunt, M. & Macfarlane, G. J. The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int. J. Epidemiol. 35, 468–476 (2006).
Nimnuan, C., Hotopf, M. & Wessely, S. Medically unexplained symptoms: an epidemiological study in seven specialities. J. Psychosom. Res. 51, 361–367 (2001).
Creed, F. & Barsky, A. A systematic review of the epidemiology of somatisation disorder and hypochondriasis. J. Psychosom. Res. 56, 391–408 (2004).
Haller, H., Cramer, H., Lauche, R. & Dobos, G. Somatoform disorders and medically unexplained symptoms in primary care. Dtsch. Arztebl. Int. 112, 279–287 (2015).
Reid, S., Wessely, S., Crayford, T. & Hotopf, M. Medically unexplained symptoms in frequent attenders of secondary health care: retrospective cohort study. BMJ 322, 767 (2001).
Rosendal, M., Olesen, F. & Fink, P. Management of medically unexplained symptoms. BMJ 330, 4–5 (2005).
Barsky, A. J., Orav, E. J. & Bates, D. W. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch. Gen. Psychiatry 62, 903–910 (2005).
Olde Hartman, T. C. et al. Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis. A systematic review. J. Psychosom. Res. 66, 363–377 (2009).
Bermingham, S. L., Cohen, A., Hague, J. & Parsonage, M. The cost of somatisation among the working-age population in England for the year 2008-2009. Ment. Health Fam. Med. 7, 71–84 (2010).
Stone, L. Blame, shame and hopelessness: medically unexplained symptoms and the ‘heartsink’ experience. Aust. Fam. Physician 43, 191–195 (2014).
Rosendal, M. et al. Medically unexplained’ symptoms and symptom disorders in primary care: prognosis-based recognition and classification. BMC Fam. Pract. 18, 18 (2017).
Johansen, M.-L. & Risor, M. B. What is the problem with medically unexplained symptoms for GPs? A meta-synthesis of qualitative studies. Patient Educ. Couns. 100, 647–654 (2017).
Salmon, P., Peters, S. & Stanley, I. Patients’ perceptions of medical explanations for somatisation disorders: qualitative analysis. BMJ 318, 372–376 (1999).
Page, L. A. & Wessely, S. Medically unexplained symptoms: exacerbating factors in the doctor–patient encounter. J. R. Soc. Med. 96, 223–227 (2003).
Aamland, A., Malterud, K. & Werner, E. L. Patients with persistent medically unexplained physical symptoms: a descriptive study from Norwegian general practice. BMC Fam. Pract. 15, 107 (2014).
Stone, L. Managing the consultation with patients with medically unexplained symptoms: a grounded theory study of supervisors and registrars in general practice. BMC Fam. Pract. 15, 192 (2014).
Chew-Graham, C. A. et al. Medically unexplained symptoms: continuing challenges for primary care. Br. J. Gen. Pract. 67, 106–107 (2017).
Salmon, P., Dowrick, C. F., Ring, A. & Humphris, G. M. Voiced but unheard agendas: qualitative analysis of the psychosocial cues that patients with unexplained symptoms present to general practitioners. Br. J. Gen. Pract. 54, 171–176 (2004).
van der Weijden, T., van Velsen, M., Dinant, G.-J., van Hasselt, C. M. & Grol, R. Unexplained complaints in general practice: prevalence, patients’ expectations, and professionals’ test-ordering behavior. Med. Decis. Mak. 23, 226–231 (2003).
Burton, C., McGorm, K., Richardson, G., Weller, D. & Sharpe, M. Healthcare costs incurred by patients repeatedly referred to secondary medical care with medically unexplained symptoms: a cost of illness study. J. Psychosom. Res. 72, 242–247 (2012).
Rosendal, M. et al. Enhanced care by generalists for functional somatic symptoms and disorders in primary care. Cochrane Database Syst. Rev. 2013, CD008142 (2013).
Saunders, C. et al. Explanations for functional somatic symptoms across European treatment settings: a mixed methods study. J. Psychosom. Res. 166, 111155 (2023).
Saunders, C. et al. Participatory design of bodysymptoms.org: an interactive web resource to explain multisystem functional somatic symptoms. J. Psychosom. Res. 183, 111827 (2024).
Saunders, C., Pedersen, H. F., Rask, C. U., Greco, M. & Frostholm, L. Embodied wisdom: towards acceptable and helpful explanations for functional somatic symptoms. Med. Humanit. 52, 234–244 (2026).
Tattan, M., Gol, J. M., Van Tol, D., Hanssen, D. J. C. & Rosmalen, J. G. M. ‘Fibromyalgia, a life companion that you don’t want to have’: a qualitative study on the impact of receiving a diagnostic label of Fibromyalgia from a patient perspective. J. Health Psychol. https://doi.org/10.1177/13591053251409603. (2026).
Tran, V.-T. & Ravaud, P. COllaborative open platform E-cohorts for research acceleration in trials and epidemiology. J. Clin. Epidemiol. 124, 139–148 (2020).
Toussaint, A. et al. Development and validation of the Somatic Symptom Disorder-B Criteria Scale (SSD-12). Psychosom. Med. 78, 5–12 (2016).
EuroQol Group EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16, 199–208 (1990).
Janssen, M. F., Bonsel, G. J. & Luo, N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics 36, 675–697 (2018).
Braun, V. & Clarke, V. Using thematic analysis in psychology. Qual. Res. Psychol. 3, 77–101 (2006).
Yin, R. K. Qualitative Research from Start to Finish, 2nd edn, 386 (The Guilford Press, 2016).
Budtz-Lilly, A. et al. Bodily distress syndrome: a new diagnosis for functional disorders in primary care? BMC Fam. Pract. 16, 180 (2015).
Baromètre santé 2021. https://www.santepubliquefrance.fr/etudes-et-enquetes/barometres-de-sante-publique-france/barometre-sante-2021.
Kop, W. J., Toussaint, A., Mols, F. & Löwe, B. Somatic symptom disorder in the general population: associations with medical status and health care utilization using the SSD-12. Gen. Hosp. Psychiatry 56, 36–41 (2019).
Stone, J. et al. What should we say to patients with symptoms unexplained by disease? The “number needed to offend”. BMJ 325, 1449–1450 (2002).
Polakovská, L. & Řiháček, T. What is it like to live with medically unexplained physical symptoms? A qualitative meta-summary. Psychol. Health 37, 580–596 (2022).
Houwen, J. et al. Medically unexplained symptoms: time to and triggers for diagnosis in primary care consultations. Br. J. Gen. Pract. 70, e86–e94 (2020).
Kirmayer, L. J., Groleau, D., Looper, K. J. & Dao, M. D. Explaining medically unexplained symptoms. Can. J. Psychiatry 49, 663–672 (2004).
Stone, J., Burton, C. & Carson, A. Recognising and explaining functional neurological disorder. BMJ 371, m3745 (2020).
Nettleton, S., O’Malley, L., Watt, I. & Duffey, P. Enigmatic illness: narratives of patients who live with medically unexplained symptoms. Soc. Theory Health 2, 47–66 (2004).
Stone, L. Managing medically unexplained illness in general practice. Aust. Fam. Physician 44, 624–629 (2015).
Houwen, J. et al. Improving GP communication in consultations on medically unexplained symptoms: a qualitative interview study with patients in primary care. Br. J. Gen. Pract. 67, e716–e723 (2017).
Mcloughlin, C., Lee, W. H., Carson, A. & Stone, J. Iatrogenic harm in functional neurological disorder. Brain 148, 27–38 (2025).
Veldmeijer, L., Terlouw, G., Boonstra, N. & van Os, J. Opening doors or building cages? The adverse consequences of psychiatric diagnostic labels. Curr. Opin. Psychol. 65, 102076 (2025).
Ranque, B. & Nardon, O. Prise en charge des symptômes médicalement inexpliqués en médecine interne: un paradigme de la relation médecin-malade en situation d’incertitude - EM consulte. Rev. Méd. Interne 38, 458–466 (2017).
Terpstra, T. et al. Explanations for medically unexplained symptoms: a qualitative study on GPs in daily practice consultations. Fam. Pract. 37, 124–130 (2020).
Larun, L., Brurberg, K. G., Odgaard-Jensen, J. & Price, J. R. Exercise therapy for chronic fatigue syndrome. Cochrane Library. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003200.pub8/full. (2019).
Arnold, L. M. et al. Comorbidity of fibromyalgia and psychiatric disorders. J. Clin. Psychiatry 67, 1219–1225 (2006).
Lumley, M. A., Stettner, L. & Wehmer, F. How are alexithymia and physical illness linked? A review and critique of pathways. J. Psychosom. Res. 41, 505–518 (1996).
Olde Hartman, T. C., Hassink-Franke, L. J., Lucassen, P. L., van Spaendonck, K. P. & van Weel, C. Explanation and relations. How do general practitioners deal with patients with persistent medically unexplained symptoms: a focus group study. BMC Fam. Pract. 10, 68 (2009).
Weiland, A. et al. Training medical specialists to communicate better with patients with medically unexplained physical symptoms (MUPS). A randomized, controlled trial. PLoS ONE 10, e0138342 (2015).
Mariman, A., Vermeir, P., Csabai, M. & Weiland, A. Perceptions and attitudes of health care givers and patients on medically unexplained symptoms: a narrative review with a focus on cultural diversity and migrants. Medical & Clinical Research 6, 461–465 (2021).
Abrahamsen, C., Reme, S. E., Wangen, K. R., Lindbæk, M. & Werner, E. L. The effects of a structured communication tool in patients with medically unexplained physical symptoms: a cluster randomized trial. EClinicalMedicine 65, 102262 (2023).
Gotlieb, R. et al. Accuracy in patient understanding of common medical phrases. JAMA Netw. Open 5, e2242972 (2022).
Woivalin, T., Krantz, G., Mäntyranta, T. & Ringsberg, K. C. Medically unexplained symptoms: perceptions of physicians in primary health care. Fam. Pract. 21, 199–203 (2004).
Acknowledgements
We sincerely thank patient partners Sabine Paulhet and Claudine Bristol for their invaluable contribution to this study. Their careful review of the questionnaire and their thoughtful feedback were essential in improving its clarity, relevance, and alignment with patients’ experiences.
Author information
Authors and Affiliations
METHODS Team, CRESS, INSERM, INRAE, Université Paris Cité, Paris, France
Elise Rambaud, Viet-Thi Tran, Tiphaine Lenfant & Brigitte Ranque
Equipe Mobile de Soins Palliatifs, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
Elise Rambaud
Centre d’Epidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, Paris, France
Viet-Thi Tran
Médecine Interne, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
Tiphaine Lenfant & Brigitte Ranque
Authors
- Elise Rambaud
- Viet-Thi Tran
- Tiphaine Lenfant
- Brigitte Ranque
Contributions
E.R., B.R. and V.T.T. conceived the study and designed the research. E.R., T.L. and B.R. performed the qualitative analyses, with the help of V.T.T. E.R. drafted the manuscript. E.R., B.R., V.T.T. and T.L. contributed to data interpretation, critically revised the manuscript, and approved the final version.
Corresponding author
Correspondence to Elise Rambaud.
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Communications Medicine thanks Tara M Petzke, Harald Merckelbach, and Anne Weiland for their contribution to the peer review of this work. A peer review file is available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Rambaud, E., Tran, VT., Lenfant, T. et al. Patients’ experience with medical communication about medically unexplained symptoms. Commun Med 6, 462 (2026). https://doi.org/10.1038/s43856-026-01852-8
Received: 18 March 2026
Accepted: 30 July 2026
Published: 01 October 2026
Version of record: 01 October 2026
DOI: https://doi.org/10.1038/s43856-026-01852-8
来源:Nature 健康护理主题 · nature.com